Cargando…

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199

OBJECTIVE: Chronic lymphoid leukemia (CLL) is the most common type of leukemia among adults. Increased levels of Mcl-1 and Bcl-xL is linked to resistance to Bcl-2 inhibitors including ABT-199. In this study, we investigated the effect of miRNA-16-1 on apoptosis and sensitivity of the CLL cells to AB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ashofteh, Nooshin, Sayed Ali Mehbod, Amir, Bayat, Mohammad, Karami, Hadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Royan Institute 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468723/ https://www.ncbi.nlm.nih.gov/pubmed/36093807 http://dx.doi.org/10.22074/cellj.2022.8101

Ejemplares similares

MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells
por: Ashofteh, Nooshin, et al.
Publicado: (2021)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
por: Masilamani, Anie P., et al.
Publicado: (2020)

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1
por: Li, Lingxiao, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Luedtke, Daniel A, et al.
Publicado: (2017)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
por: Pallis, Monica, et al.
Publicado: (2016)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2011)

Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737
por: Shahverdi, Mahshid, et al.
Publicado: (2020)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1
por: Luedtke, Daniel A., et al.
Publicado: (2018)

By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737
por: Tailler, Maximilien, et al.
Publicado: (2018)

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
por: Choudhary, G S, et al.
Publicado: (2015)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014)

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2018)

A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells
por: Grundy, Martin, et al.
Publicado: (2020)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine
por: Stamelos, Vasileios A, et al.
Publicado: (2012)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER(+) breast cancer
por: Deng, Jing, et al.
Publicado: (2013)

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rsk4uh0c3sg9a4ao8tolvt9ruo